Skip to main content
HCPCS Q2050 · Level II · Part B drug

HCPCS Q2050: Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for Q2050

Billing unit
10 MG
Doxorubicin inj 10mg
ASP payment limit
$97.823
October 2026; -16.1% vs July 2026
Practitioner MUE
14
MAI 3
OPPS status
SI K
APC 7046
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q2050 is the Level II code for Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $97.823 per billing unit, down 16.1% from July 2026. The practitioner MUE allows up to 14 units per date of service (MAI 3). Under OPPS it carries status indicator K in APC 7046. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. The ASP crosswalk maps 30 NDCs to it, sold as Doxil, Doxorubicin HCl, Liposomal, Doxorubicin HCl Liposome by Baxter Healthcare Corporation, Northstar RxLLC, Sagent Pharmaceuticals. No current Billing and Coding Article lists Q2050, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q2050 at $97.823 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $116.605 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q2050
QuarterPayment limitPerCoinsurance
October 2026$97.82310 MG20%
July 2026$116.60510 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 30 NDCs from 9 labelers to Q2050. Report the NDC in the claim's drug segment and bill the number of Q2050 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to Q2050
NDCDrug nameLabelerPackage sizeBilling units / package
00338-0063-01DoxilBaxter Healthcare Corporation10 × 12
00338-0067-01DoxilBaxter Healthcare Corporation25 × 15
00338-9665-01DoxilBaxter Healthcare Corporation25 × 15
00338-9667-01DoxilBaxter Healthcare Corporation10 × 12
16714-0742-01Doxorubicin HCl, LiposomalNorthstar RxLLC10 × 12
16714-0856-01Doxorubicin HCl, LiposomalNorthstar RxLLC25 × 15
25021-0263-10Doxorubicin HCl, LiposomalSagent Pharmaceuticals10 × 12
25021-0263-25Doxorubicin HCl, LiposomalSagent Pharmaceuticals25 × 15
43598-0283-35Doxorubicin HCl, LiposomalDr. Reddy's Laboratories Inc.10 × 12
43598-0541-25Doxorubicin HCl, LiposomalDr. Reddy's Laboratories Inc.25 × 15
43598-0682-35Doxorubicin HCl, LiposomalDr. Reddy's Laboratories Inc.10 × 12
43598-0683-25Doxorubicin HCl, LiposomalDr. Reddy's Laboratories Inc.25 × 15
47335-0049-40Doxorubicin HCl, LiposomalSun Pharmaceutical Global FZE.10 × 12
47335-0050-40Doxorubicin HCl, LiposomalSun Pharmaceutical Global FZE.25 × 15
68001-0345-26Doxorubicin HCl, LiposomalBluePoint Laboratories25 × 15
68001-0345-36Doxorubicin HCl, LiposomalBluePoint Laboratories10 × 12
68001-0492-36Doxorubicin HCl, LiposomalBluePoint Laboratories10 × 12
68001-0493-26Doxorubicin HCl, LiposomalBluePoint Laboratories25 × 15
68001-0629-26Doxorubicin HCl LiposomeBluepoint Laboratories25 × 15
68001-0629-36Doxorubicin HCl LiposomeBluepoint Laboratories10 × 12
68001-0703-36Doxorubicin HCl, LiposomalBluePoint Laboratories10 × 12
68001-0704-26Doxorubicin HCl, LiposomalBluePoint Laboratories25 × 15
70710-1530-01Doxorubicin HCl, LiposomalZydus Pharmaceuticals (USA) Inc.10 × 12
70710-1531-01Doxorubicin HCl, LiposomalZydus Pharmaceuticals (USA) Inc.25 × 15
70748-0339-01Doxorubicin HCl, LiposomalLupin Pharmaceuticals, Inc.10 × 12
70748-0340-01Doxorubicin HCl, LiposomalLupin Pharmaceuticals, Inc.25 × 15
72603-0103-01Doxorubicin HCl, LiposomalNorthstar RxLLC10 × 12
72603-0200-01Doxorubicin HCl, LiposomalNorthstar RxLLC25 × 15
75907-0363-01Doxorubicin HCl, LiposomalDr. Reddy's Laboratories Inc.10 × 12
75907-0364-01Doxorubicin HCl, LiposomalDr. Reddy's Laboratories Inc.25 × 15

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for Q2050. For practitioners the limit is 14 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for Q2050 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services143 Date of Service Edit: ClinicalClinical: CMS Workgroup
Facility outpatient hospital203 Date of Service Edit: ClinicalClinical: CMS Workgroup
DME supplier03 Date of Service Edit: ClinicalPublished Contractor Policy

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q2050 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

Q2050 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q2050 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, Q2050 carries status indicator K and is assigned to APC 7046, with a published national unadjusted payment of $116.61. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for Q2050 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks Q2050 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS Q2050

What does HCPCS code Q2050 describe?

Q2050 is defined by CMS as "Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for Q2050 in October 2026?

The ASP-based payment limit is $97.823 per 10 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $116.605.

How many units of Q2050 can be billed per day?

The practitioner Medically Unlikely Edit is 14 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: CMS Workgroup" as the rationale.

Which NDCs map to Q2050?

The October 2026 ASP crosswalk lists 30 NDCs from 9 labelers: Doxil (Baxter Healthcare Corporation); Doxorubicin HCl, Liposomal (Northstar RxLLC); Doxorubicin HCl, Liposomal (Sagent Pharmaceuticals); Doxorubicin HCl, Liposomal (Dr. Reddy's Laboratories Inc.). For example NDC 00338-0063-01 is a 10 package equal to 2 billing units. The crosswalk's billing-units-per-package figure converts each package into Q2050 units.

Does Q2050 have NCCI bundling edits?

No active practitioner PTP pairs list Q2050 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.